Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Microsatellite Instability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Microsatellite Instability. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2013-005086-40 Sponsor Protocol Number: J1214 Start Date*: 2014-05-21
    Sponsor Name:Sidney kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or...
    Medical condition: relapsed or refractory metastatic colorectal adenocarcinoma with methylation of CHFR and/or microsatellite instability
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003440-92 Sponsor Protocol Number: INFINITY Start Date*: 2020-12-22
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, sing...
    Medical condition: The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classifica...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10073379 Tubular adenocarcinoma gastric LLT
    20.0 100000004864 10073378 Signet-ring cell adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003939-30 Sponsor Protocol Number: CA209-142 Start Date*: 2014-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
    Medical condition: MSI Positive Colorectal Cancer MSI Negative Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Ongoing) IE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002823-40 Sponsor Protocol Number: NOUS-209-01 Start Date*: 2021-12-21
    Sponsor Name:Nouscom S.r.l.
    Full Title: A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
    Medical condition: Locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who are eligible for anti-PD-1 1st line of treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002024-89 Sponsor Protocol Number: 3475-177 Start Date*: 2015-12-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
    Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) DE (Completed) FI (Completed) SE (Completed) IE (Ongoing) DK (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000040-26 Sponsor Protocol Number: CA209-8HW Start Date*: 2019-07-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-...
    Medical condition: Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing) IE (Completed) FR (Trial now transitioned) DK (Trial now transitioned) ES (Restarted) CZ (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006073-24 Sponsor Protocol Number: CCR2983 Start Date*: 2008-05-22
    Sponsor Name:Royal Marsden Hospital
    Full Title: CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment: A Phase II Study of Epothilone B in Metastatic Colon Carcinoma in patients with Microsatellite Instability or Chromosomal Inst...
    Medical condition: Metastatic or locally recurrent colorectal cancer in genetically unselected patients, followed by recruitment of patients selected for microsatellite positive tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010035 Colorectal cancer stage IV LLT
    9.1 10010030 Colorectal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000974-44 Sponsor Protocol Number: D910CC00001 Start Date*: 2019-10-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer ...
    Medical condition: Metastatic Microsatellite-Stable Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000589-31 Sponsor Protocol Number: NEMESIS Start Date*: 2018-02-02
    Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA
    Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005584-33 Sponsor Protocol Number: KUN2009 Start Date*: 2010-02-09
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI
    Medical condition: In this study our primary objective is to induce or enhance an immune response to tumor antigens in Lynch syndrome mutation carriers (with and without colorectal adenomas or carcinomas) and patient...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-003708-33 Sponsor Protocol Number: ML43332 Start Date*: 2023-03-15
    Sponsor Name:Roche Farma S.A.U.
    Full Title: A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RE...
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001852-32 Sponsor Protocol Number: 3475-164 Start Date*: 2015-12-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite I...
    Medical condition: Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005114-18 Sponsor Protocol Number: MK-1308A-008 Start Date*: 2021-07-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-...
    Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079619 MSI-high LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) BE (Ongoing) IT (Ongoing) ES (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002442-72 Sponsor Protocol Number: C17-01 Start Date*: 2017-10-23
    Sponsor Name:GERCOR
    Full Title: RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab. A GERCOR open-label phase II study NIPICOL C17-01
    Medical condition: Patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000158-88 Sponsor Protocol Number: 2019-013-GLOB1 Start Date*: 2020-07-27
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients wit...
    Medical condition: Refractory metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Completed) DE (Completed) AT (Completed) BE (Completed) IT (Ongoing) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001136-28 Sponsor Protocol Number: OSE-279-C101 Start Date*: 2022-11-08
    Sponsor Name:OSE Immunotherapeutics
    Full Title: A multicenter, phase 1/2, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas
    Medical condition: Advanced solid tumors and lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003115-21 Sponsor Protocol Number: 2018/2798 Start Date*: 2019-02-19
    Sponsor Name:Gustave Roussy
    Full Title: A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors
    Medical condition: Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004575-49 Sponsor Protocol Number: FFCD-1603 Start Date*: 2017-07-11
    Sponsor Name:Federation Francophone de Cancerologie Digestive
    Full Title: MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROS...
    Medical condition: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004403-31 Sponsor Protocol Number: MITOEND-3 Start Date*: 2022-03-24
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: MITO END-3: A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer
    Medical condition: advanced (stage III-IV) or recurrent endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007342 Carcinoma endometrial LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002344-81 Sponsor Protocol Number: 1381-0009 Start Date*: 2019-05-22
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with ad...
    Medical condition: Advanced/metastatic solid tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA